05/23/2013:
Elan Announces Pricing of US$850 Million in Aggregate Principal Amount of Senior Notes Due 2021 More.
05/23/2013:
Elan Corporation, plc' s Board of Directors Unanimously Reject Royalty Pharma' s Revised Tender Offer More.
05/20/2013:
Elan's Response to Royalty Pharma Announcement More.
